Radalbuvir

Radalbuvir (INN, also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials. It targets NS5B polymerase.